Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13141241 | 0.86 | TP53 (0.48) | HTR2CGRM2DRD2LIPESIGMAR1 | |
| SCHEMBL6884365 | 0.82 | HTR2C (0.58) | HTR2CGRM2DRD2DRD4LIPE | |
| SCHEMBL14445324 | 0.82 | MAPK14 (0.41) | GRM2DRD2TACR1 | |
| SCHEMBL18700713 | 0.80 | LIPE (0.41) | HTR2CGRM2DRD2DRD4LIPE | |
| SCHEMBL18700291 | 0.80 | LIPE (0.45) | LIPEP2RY14 | |
| SCHEMBL18707815 | 0.80 | SLC18A3 (0.50) | DRD2DRD4LIPETP53 | |
| SCHEMBL1847401 | 0.79 | HTR2C (0.73) | HTR2C | |
| SCHEMBL15528823 | 0.79 | SLC18A3 (0.49) | DRD2 | |
| SCHEMBL3929472 | 0.79 | TP53 (0.51) | TP53 | |
| SCHEMBL18714255 | 0.79 | DRD2 (0.57) | GRM2DRD2DRD4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507494-B2 | Heterocyclic quinolizine derived M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130040959-A1 | Heterocyclic Quinolizine Derived M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040959-A1 | Heterocyclic Quinolizine Derived M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, CHRNA5 | HTR2C 47/4885GRM2 96/4885DRD2 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.